AU2001253206A1 - Ns5b hcv polymerase inhibitors - Google Patents

Ns5b hcv polymerase inhibitors

Info

Publication number
AU2001253206A1
AU2001253206A1 AU2001253206A AU5320601A AU2001253206A1 AU 2001253206 A1 AU2001253206 A1 AU 2001253206A1 AU 2001253206 A AU2001253206 A AU 2001253206A AU 5320601 A AU5320601 A AU 5320601A AU 2001253206 A1 AU2001253206 A1 AU 2001253206A1
Authority
AU
Australia
Prior art keywords
hcv polymerase
polymerase inhibitors
ns5b hcv
ns5b
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253206A
Inventor
Juan C. Jaen
Yang Li
Derek E. Piper
Jay P. Powers
Nigel P. C. Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tularik Inc
Original Assignee
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc filed Critical Tularik Inc
Publication of AU2001253206A1 publication Critical patent/AU2001253206A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
AU2001253206A 2000-04-05 2001-04-05 Ns5b hcv polymerase inhibitors Abandoned AU2001253206A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19491200P 2000-04-05 2000-04-05
US60194912 2000-04-05
PCT/US2001/011240 WO2001077091A2 (en) 2000-04-05 2001-04-05 Ns5b hcv polymerase inhibitors

Publications (1)

Publication Number Publication Date
AU2001253206A1 true AU2001253206A1 (en) 2001-10-23

Family

ID=22719370

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253206A Abandoned AU2001253206A1 (en) 2000-04-05 2001-04-05 Ns5b hcv polymerase inhibitors

Country Status (3)

Country Link
US (1) US6727267B2 (en)
AU (1) AU2001253206A1 (en)
WO (1) WO2001077091A2 (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2387172A (en) * 2002-03-28 2003-10-08 Pantherix Ltd [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials
BR0305259A (en) * 2002-07-01 2004-10-05 Upjohn Co Hcv ns5b polymerase inhibitors
US7041690B2 (en) 2002-07-01 2006-05-09 Pharmacia & Upjohn Company, Llc Inhibitors of HCV NS5B polymerase
US20060276520A1 (en) * 2002-11-13 2006-12-07 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
AU2003295605A1 (en) * 2002-11-19 2004-06-15 Achillion Pharmaceuticals, Inc. Substituted aryl thioureas and releated compounds; inhibitors of viral replication
US20050009877A1 (en) * 2003-05-15 2005-01-13 Henry Lu Methods of identifying HCV NS5B polymerase inhibitors and their uses
EP1651226B1 (en) 2003-07-11 2010-02-24 Proteologics, Inc. Ubiquitin ligase inhibitors and methods related thereto
US7566732B2 (en) 2003-10-28 2009-07-28 Rigel Pharmaceuticals, Inc. Rhodanine compositions for use as antiviral agents
US7026339B2 (en) 2003-11-07 2006-04-11 Fan Yang Inhibitors of HCV NS5B polymerase
WO2005049622A1 (en) * 2003-11-19 2005-06-02 Japan Tobacco Inc. 5-5-membered fused heterocyclic compound and use thereof as hcv polymerase inhibitor
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
EP1718608B1 (en) 2004-02-20 2013-07-17 Boehringer Ingelheim International GmbH Viral polymerase inhibitors
DE602005013922D1 (en) 2004-02-24 2009-05-28 Japan Tobacco Inc CONDENSED HETEROTETRACYCLIC COMPOUNDS AND THEIR USE AS HCV POLYMERASE INHIBITOR
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
EP1758453B1 (en) 2004-06-15 2014-07-16 Merck Sharp & Dohme Corp. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
CA2571079A1 (en) 2004-06-24 2006-02-02 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
WO2006095713A1 (en) * 2005-03-08 2006-09-14 Institute Of Medicinal Molecular Design. Inc. Inhibitor of plasminogen activator inhibitor-1
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
EP1879885A1 (en) 2005-05-04 2008-01-23 F. Hoffmann-Roche AG Heterocyclic antiviral compounds
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
AU2006275605B2 (en) 2005-08-01 2011-01-06 Merck Sharp & Dohme Corp. Macrocyclic peptides as HCV NS3 protease inhibitors
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
CN101573370B (en) 2006-10-10 2013-09-11 美迪维尔公司 HCV nucleoside inhibitor
US8309540B2 (en) 2006-10-24 2012-11-13 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
JP2010507656A (en) 2006-10-24 2010-03-11 メルク エンド カムパニー インコーポレーテッド HCV NS3 protease inhibitor
ES2444575T3 (en) 2006-10-27 2014-02-25 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
KR101615500B1 (en) 2006-10-27 2016-04-27 머크 샤프 앤드 돔 코포레이션 HCV NS3 protease inhibitors
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008075103A1 (en) 2006-12-20 2008-06-26 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Antiviral indoles
JP2010515680A (en) 2007-01-05 2010-05-13 メルク・シャープ・エンド・ドーム・コーポレイション Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infections
ES2381410T3 (en) 2007-05-04 2012-05-28 Vertex Pharmceuticals Incorporated Combination therapy for the treatment of HCV infections
CA2693533A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis c infections
WO2009010804A1 (en) 2007-07-19 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic compounds as antiviral agents
US8309685B2 (en) * 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8293705B2 (en) * 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
JP5755449B2 (en) * 2007-12-21 2015-07-29 セルジーン アビロミクス リサーチ， インコーポレイテッド HCV protease inhibitors and uses thereof
TWI487522B (en) * 2007-12-21 2015-06-11 賽基艾維洛米斯研究股份有限公司 Hcv protease inhibitors and uses thereof
US8236838B2 (en) 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US8207205B2 (en) 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
AU2009241445A1 (en) 2008-04-28 2009-11-05 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
RS53420B (en) 2008-07-22 2014-12-31 Msd Italia S.R.L. Combinations of a macrocyclic quinoxaline compound which is an hcv ns3 protease inhibitor with other hcv agents
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
US20120219613A1 (en) * 2009-03-23 2012-08-30 The Regents Of The University Of California Novel Antiviral Agents for Enveloped Viruses
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
WO2011014487A1 (en) 2009-07-30 2011-02-03 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
US20110052534A1 (en) * 2009-08-31 2011-03-03 Martin Leivers Imidazopyridazine Compounds for Treating Viral Infections
MX2012005528A (en) 2009-11-14 2012-06-12 Hoffmann La Roche Biomarkers for predicting rapid response to hcv treatment.
SG181104A1 (en) 2009-12-02 2012-07-30 Hoffmann La Roche Biomarkers for predicting sustained response to hcv treatment
WO2011130419A2 (en) 2010-04-13 2011-10-20 The Regents Of The University Of California Broad spectrum antiviral and antiparasitic agents
US9255088B2 (en) 2010-08-11 2016-02-09 The Regents Of The University Of California Premature-termination-codons readthrough compounds
JP6014816B2 (en) * 2011-05-10 2016-10-26 国立大学法人神戸大学 Thioxothiazolidine derivative having Ras function inhibitory action
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
EP2780026B1 (en) 2011-11-15 2019-10-23 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
WO2013106344A1 (en) 2012-01-12 2013-07-18 Ligand Pharmaceuticals, Inc. 2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5'
WO2013142346A1 (en) 2012-03-23 2013-09-26 The Regents Of The University Of California Premature-termination-codons readthrough compounds
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121416A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
RU2534613C2 (en) 2013-03-22 2014-11-27 Александр Васильевич Иващенко Alkyl2-{[(2r,3s,5r)-5-(4-amino-2-oxo-2h-pyrimidine-1-yl)- -hydroxy- tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-proptonates, nucleoside inhibitors of rna-polymerase hcv ns5b, methods for producing and using them
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
JP2017520545A (en) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド Prodrug compounds and their use
GB201415569D0 (en) 2014-09-03 2014-10-15 C4X Discovery Ltd Therapeutic Compounds
WO2016077793A1 (en) * 2014-11-14 2016-05-19 Children's Hospital Medical Center Sos1 inhibitors for cancer treatment
CR20170420A (en) 2015-03-13 2017-10-03 Forma Therapeutics Inc ALFA-CINAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS
GB201601703D0 (en) 2016-01-29 2016-03-16 C4X Discovery Ltd Therapeutic compounds
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
TW202322824A (en) 2020-02-18 2023-06-16 美商基利科學股份有限公司 Antiviral compounds
CN117120444A (en) 2021-04-16 2023-11-24 吉利德科学公司 Method for preparing carbanucleoside using amide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2949464A (en) * 1959-02-02 1960-08-16 Upjohn Co 3-amino-5-(para-hydroxy-benzylidene) rhodanine
CA2110251A1 (en) * 1992-11-30 1994-05-31 Koichi Fujimoto Alpha, omega-diarylalkane derivatives, their preparation and their use in the treatment and prevention of circulatory diseases and psychosis
WO2000006529A1 (en) 1998-07-27 2000-02-10 Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. Diketoacid-derivatives as inhibitors of polymerases
KR20010099623A (en) 1998-08-21 2001-11-09 비로파마 인코포레이티드 Compounds, compositions and methods for treating or preventing viral infections and associated diseases

Also Published As

Publication number Publication date
US6727267B2 (en) 2004-04-27
US20020142290A1 (en) 2002-10-03
WO2001077091A3 (en) 2002-03-21
WO2001077091A2 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
AU2001253206A1 (en) Ns5b hcv polymerase inhibitors
AU2001272258A1 (en) Viral polymerase inhibitors
AU2003265255A1 (en) Inhibitors of hcv ns5b polymerase
AU2003256334A1 (en) Inhibitors of hcv ns5b polymerase
IL222761A0 (en) Viral polymerase inhibitors
AU2001258771A1 (en) -secretase inhibitors
AU2003224836A1 (en) Dual-labeled nucleotides
AU2001296961A1 (en) 17-beta-hydroxysteroid dehydrogenase-ii inhibitors
AU2001293373A1 (en) 2-guanidino-4-arylchinazolines as NHE-3 inhibitors
HUP0400039A3 (en) Hcv polymerase inhibitor assay
AU2001231682A1 (en) Surfactant combination
AU4657001A (en) Displacing arrangement
AU5248800A (en) Fading inhibitors
AU2002220553A1 (en) Bioreactor
AU2001293214A1 (en) Heatsink retainer
AU2001262729A1 (en) 4-oxoimidazolidine-2-spiro-nitrogenous heterocycle compounds
AU2001284545A1 (en) Navigator
AU2002222139A1 (en) Hcv vaccines
AU2001286120A1 (en) Interferon-alpha induced gene
AU2002222187A1 (en) Interferon-alpha induced gene
AU2001254563A1 (en) Internal de novo initiation sites of the hcv ns5b polymerase and use thereof
AU2002307960A1 (en) Nucleoside compounds in hcv
AU7246701A (en) Novel telomerase inhibitors
AU2002354843A1 (en) Viral polymerase inhibitors
AUPR282501A0 (en) Expression facilitating nucleotides